580 related articles for article (PubMed ID: 32826343)
1. Natural killer cell immunotypes related to COVID-19 disease severity.
Maucourant C; Filipovic I; Ponzetta A; Aleman S; Cornillet M; Hertwig L; Strunz B; Lentini A; Reinius B; Brownlie D; Cuapio A; Ask EH; Hull RM; Haroun-Izquierdo A; Schaffer M; Klingström J; Folkesson E; Buggert M; Sandberg JK; Eriksson LI; Rooyackers O; Ljunggren HG; Malmberg KJ; Michaëlsson J; Marquardt N; Hammer Q; Strålin K; Björkström NK;
Sci Immunol; 2020 Aug; 5(50):. PubMed ID: 32826343
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 pneumonia: CD8
Jiang Y; Wei X; Guan J; Qin S; Wang Z; Lu H; Qian J; Wu L; Chen Y; Chen Y; Lin X
Clin Immunol; 2020 Sep; 218():108516. PubMed ID: 32574709
[TBL] [Abstract][Full Text] [Related]
3. Clinical Characteristics and Immune Injury Mechanisms in 71 Patients with COVID-19.
Wu Y; Huang X; Sun J; Xie T; Lei Y; Muhammad J; Li X; Zeng X; Zhou F; Qin H; Shao L; Zhang Q
mSphere; 2020 Jul; 5(4):. PubMed ID: 32669467
[TBL] [Abstract][Full Text] [Related]
4. Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19.
Osman M; Faridi RM; Sligl W; Shabani-Rad MT; Dharmani-Khan P; Parker A; Kalra A; Tripathi MB; Storek J; Cohen Tervaert JW; Khan FM
Blood Adv; 2020 Oct; 4(20):5035-5039. PubMed ID: 33075136
[TBL] [Abstract][Full Text] [Related]
5. Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies.
Market M; Angka L; Martel AB; Bastin D; Olanubi O; Tennakoon G; Boucher DM; Ng J; Ardolino M; Auer RC
Front Immunol; 2020; 11():1512. PubMed ID: 32655581
[TBL] [Abstract][Full Text] [Related]
6. Single-cell landscape of immunological responses in patients with COVID-19.
Zhang JY; Wang XM; Xing X; Xu Z; Zhang C; Song JW; Fan X; Xia P; Fu JL; Wang SY; Xu RN; Dai XP; Shi L; Huang L; Jiang TJ; Shi M; Zhang Y; Zumla A; Maeurer M; Bai F; Wang FS
Nat Immunol; 2020 Sep; 21(9):1107-1118. PubMed ID: 32788748
[TBL] [Abstract][Full Text] [Related]
7. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications.
Mathew D; Giles JR; Baxter AE; Oldridge DA; Greenplate AR; Wu JE; Alanio C; Kuri-Cervantes L; Pampena MB; D'Andrea K; Manne S; Chen Z; Huang YJ; Reilly JP; Weisman AR; Ittner CAG; Kuthuru O; Dougherty J; Nzingha K; Han N; Kim J; Pattekar A; Goodwin EC; Anderson EM; Weirick ME; Gouma S; Arevalo CP; Bolton MJ; Chen F; Lacey SF; Ramage H; Cherry S; Hensley SE; Apostolidis SA; Huang AC; Vella LA; ; Betts MR; Meyer NJ; Wherry EJ
Science; 2020 Sep; 369(6508):. PubMed ID: 32669297
[TBL] [Abstract][Full Text] [Related]
8. Immunological and inflammatory profiles in mild and severe cases of COVID-19.
Song JW; Zhang C; Fan X; Meng FP; Xu Z; Xia P; Cao WJ; Yang T; Dai XP; Wang SY; Xu RN; Jiang TJ; Li WG; Zhang DW; Zhao P; Shi M; Agrati C; Ippolito G; Maeurer M; Zumla A; Wang FS; Zhang JY
Nat Commun; 2020 Jul; 11(1):3410. PubMed ID: 32641700
[TBL] [Abstract][Full Text] [Related]
9. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent.
Mazzoni A; Salvati L; Maggi L; Capone M; Vanni A; Spinicci M; Mencarini J; Caporale R; Peruzzi B; Antonelli A; Trotta M; Zammarchi L; Ciani L; Gori L; Lazzeri C; Matucci A; Vultaggio A; Rossi O; Almerigogna F; Parronchi P; Fontanari P; Lavorini F; Peris A; Rossolini GM; Bartoloni A; Romagnani S; Liotta F; Annunziato F; Cosmi L
J Clin Invest; 2020 Sep; 130(9):4694-4703. PubMed ID: 32463803
[TBL] [Abstract][Full Text] [Related]
10. A single-cell atlas of the peripheral immune response in patients with severe COVID-19.
Wilk AJ; Rustagi A; Zhao NQ; Roque J; Martínez-Colón GJ; McKechnie JL; Ivison GT; Ranganath T; Vergara R; Hollis T; Simpson LJ; Grant P; Subramanian A; Rogers AJ; Blish CA
Nat Med; 2020 Jul; 26(7):1070-1076. PubMed ID: 32514174
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 Spike 1 Protein Controls Natural Killer Cell Activation via the HLA-E/NKG2A Pathway.
Bortolotti D; Gentili V; Rizzo S; Rotola A; Rizzo R
Cells; 2020 Aug; 9(9):. PubMed ID: 32859121
[TBL] [Abstract][Full Text] [Related]
12. Immune dysfunction following COVID-19, especially in severe patients.
Song CY; Xu J; He JQ; Lu YQ
Sci Rep; 2020 Sep; 10(1):15838. PubMed ID: 32985562
[TBL] [Abstract][Full Text] [Related]
13. NK cells: A double edge sword against SARS-CoV-2.
Masselli E; Vaccarezza M; Carubbi C; Pozzi G; Presta V; Mirandola P; Vitale M
Adv Biol Regul; 2020 Aug; 77():100737. PubMed ID: 32773100
[TBL] [Abstract][Full Text] [Related]
14. Long-term infection of SARS-CoV-2 changed the body's immune status.
Lin L; Luo S; Qin R; Yang M; Wang X; Yang Q; Zhang Y; Wang Q; Zhu R; Fan H; Wang H; Hu Y; Wang L; Hu D
Clin Immunol; 2020 Sep; 218():108524. PubMed ID: 32659373
[TBL] [Abstract][Full Text] [Related]
15. Friends or foes? The knowns and unknowns of natural killer cell biology in COVID-19 and other coronaviruses in July 2020.
Manickam C; Sugawara S; Reeves RK
PLoS Pathog; 2020 Aug; 16(8):e1008820. PubMed ID: 32845937
[TBL] [Abstract][Full Text] [Related]
16. Expansion of CD56
Casado JL; Moraga E; Vizcarra P; Velasco H; Martín-Hondarza A; Haemmerle J; Gómez S; Quereda C; Vallejo A
Viruses; 2021 Dec; 14(1):. PubMed ID: 35062250
[TBL] [Abstract][Full Text] [Related]
17. Natural Killer Cell Dysfunction and Its Role in COVID-19.
van Eeden C; Khan L; Osman MS; Cohen Tervaert JW
Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32883007
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients.
Liu J; Li S; Liu J; Liang B; Wang X; Wang H; Li W; Tong Q; Yi J; Zhao L; Xiong L; Guo C; Tian J; Luo J; Yao J; Pang R; Shen H; Peng C; Liu T; Zhang Q; Wu J; Xu L; Lu S; Wang B; Weng Z; Han C; Zhu H; Zhou R; Zhou H; Chen X; Ye P; Zhu B; Wang L; Zhou W; He S; He Y; Jie S; Wei P; Zhang J; Lu Y; Wang W; Zhang L; Li L; Zhou F; Wang J; Dittmer U; Lu M; Hu Y; Yang D; Zheng X
EBioMedicine; 2020 May; 55():102763. PubMed ID: 32361250
[TBL] [Abstract][Full Text] [Related]
19. Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome-An Observational Pilot Study.
Notz Q; Schmalzing M; Wedekink F; Schlesinger T; Gernert M; Herrmann J; Sorger L; Weismann D; Schmid B; Sitter M; Schlegel N; Kranke P; Wischhusen J; Meybohm P; Lotz C
Front Immunol; 2020; 11():581338. PubMed ID: 33123167
[TBL] [Abstract][Full Text] [Related]
20. The Potential Effect of Novel Coronavirus SARS-CoV-2 on NK Cells; A Perspective on Potential Therapeutic Interventions.
Jewett A
Front Immunol; 2020; 11():1692. PubMed ID: 32754162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
